Metformina + Sitagliptina Grindeks

Metformin hydrochloride and sitagliptin, the active ingredients in Metformina + Sitagliptina Grindeks, constitute a biguanide and DPP‑4 inhibitor presented as a fixed‑dose oral tablet for oral use. The combination is indicated for the management of type 2 diabetes mellitus in adult patients when diet, exercise, and monotherapy are insufficient.

GNH USA supplies Metformina + Sitagliptina Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality, regulatory compliance and reliable delivery across multiple continents through a robust logistics network.

Metformina + Sitagliptina Grindeks is used in the management of type 2 diabetes mellitus, targeting hyperglycemia through complementary mechanisms.

- Type 2 diabetes mellitus: improves overall glycemic control when diet, exercise, and monotherapy are insufficient. - Adjunct to metformin therapy: provides additional glucose‑lowering effect for patients inadequately controlled on metformin alone. - Combination therapy with other antidiabetics: enables dual action alongside sulfonylureas, insulin or GLP‑1 agonists to achieve target HbA1c.

The combination may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea. - Headache: mild to moderate intensity. - Mild hypoglycemia: especially when used with sulfonylureas or insulin. - Upper respiratory tract infection: transient symptoms.

Serious or Rare Side Effects: - Lactic acidosis: a rare but potentially fatal metabolic complication. - Acute pancreatitis: severe abdominal pain with elevated enzymes. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Hepatic failure: signs of liver dysfunction. - Severe hypoglycemia: prolonged loss of consciousness or seizures.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

- Renal function: assess eGFR and avoid use in severe renal impairment. - Hepatic disease: use with caution; monitor liver enzymes. - Risk of lactic acidosis: contraindicated in conditions predisposing to hypoxia. - Pregnancy and lactation: discuss potential risks with the prescriber. - Drug interactions: review concomitant medications for additive hypoglycemic risk. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Metformina + Sitagliptina may interact with several drug classes, requiring careful assessment.

Major Interactions (Avoid): - Severe renal impairment: contraindicates metformin component. - Strong CYP2C8 inhibitors (e.g., gemfibrozil): may increase metformin exposure. - Concurrent use of another DPP‑4 inhibitor: duplicate pharmacologic effect.

Moderate Interactions (Monitor Closely): - Sulfonylureas or insulin: heightened risk of hypoglycemia. - Loop diuretics: may affect renal clearance of metformin. - Iodinated contrast agents: temporary discontinuation of metformin recommended. - Alcohol excess: increases lactic acidosis risk. - Beta‑blockers: may mask hypoglycemia symptoms.